Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk

British Journal of Cancer

Volumn 108, Issue 9, 2013, Pages 1778-1783

  Hung, S C ^a,b   Lai, S W ^c,d   Tsai, P Y ^b,d   Chen, P C ^b,c   Wu, H C ^c,d   Lin, W H ^a   Sung, F C ^b,d  

^a Nantou Hospital   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Benign prostatic hyperplasia; Diabetes; Interaction; Prostate cancer; Prostatitis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CHLAMYDIASIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; EPIDIDYMITIS; GONORRHEA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; TAIWAN; TESTIS DISEASE;

AGED; AGED, 80 AND OVER; ASIA; COMORBIDITY; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; RISK;

EID: 84878579050     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.184     Document Type: Article

References (39)

1. Abdel-Meguid TA, Mosli HA, Al-Maghrabi JA (2009) Prostate inflammation. Association with benign prostatic hyperplasia and prostate cancer. Saudi Med J 30: 1563-1567.
2. Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R (2009) Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 55: 864-873.
3. Australian Institute of Health and Welfare & Australasian Association of Cancer Registries (2010) Cancer in Australia: an overview. 2010. Cancer series no. 60. Cat. no. CAN 56. Canberra: AIHW. 2010.
4. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46: 3040-3052.
5. Chang RT, Kirby R, Challacombe BJ (2012) Is there a link between BPH and prostate cancer? Practitioner 256: 13-16.
6. Cheng TM (2003) Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood) 22: 61-76.
7. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867.
8. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60: 106-117.
9. Dellavedova T, Ponzano R, Racca L, Minuzzi F, Dominguez M (2010) Prostate cancer as incidental finding in transurethral resection. Arch Esp Urol 63: 855-861.
10. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, Jumbelic M, Haas GP (2008) Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 179: 1736-1740.
11. Dennis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60: 78-83.
12. Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10: 580-593.
13. Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC (2011) The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med 15: 825-836.
14. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781.
15. Gorbachinsky I, Akpinar H, Assimos DG (2010) Metabolic syndrome and urologic diseases. Rev Urol 12: e157-e180.
16. Habermacher GM, Chason JT, Schaeffer AJ (2006) Prostatitis/chronic pelvic pain syndrome. Annu Rev Med 57: 195-206.
17. Hall MC, Roehrborn CG, McConnell JD (1996) Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia? Semin Urol Oncol 14: 122-133.
18. Hammarsten J, Hogstedt B (2002) Calculated fast-growing benign prostatic hyperplasia-a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 36: 330-338.
19. Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Front Biosci 11: 1388-1413.
20. Hsing AW, Sakoda LC, Chua Jr S (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86: s843-s857.
21. Huang SP, Huang CY, Liu CC, Yu CC, Pu YS, Chueh SC, Yu HJ, Wu TT, Li CC, Huang CH, Wu WJ (2010) Clinical outcome of Taiwanese men with clinically localized prostate cancer post-radical prostatectomy: a comparison with other ethnic groups. Aging Male 13: 10-17.
22. Jacobs EJ, Newton CC, Stevens VL, Gapstur SM (2011) A large cohort study of long-term acetaminophen use and prostate cancer incidence. Cancer Epidemiol Biomarkers Prev 20: 1322-1328.
23. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ (2005) A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 97: 975-980.
24. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59: 225-249.
25. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60: 277-300.
26. Klein EA, Platz EA, Thompson IM (2007) Etiology, and prevention of prostate cancer. In Campbell-Walsh Urology, Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds), 9 edn. pp 2854-2873. Saunders Elsevier: Philadelphia, PA, USA.
27. Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European urology 51: 1202-1216.
28. Krieger JN, Nyberg Jr L, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282: 236-237.
29. McNeal JE, Redwine EA, Freiha FS, Stamey TA (1988) Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12: 897-906.
30. Mosli HA (2003) Prostate cancer in Saudi Arabia in 2002. Saudi Med J 24: 573-581.
31. Pavelic J, Zeljko Z (2002) [Prostate gland-transition zone lesions. Etiology, growth regulation, growth factors, genetic changes]. Lijec Vjesn 124: 211-219.
32. Pettaway CA, Lamerato LE, Eaddy MT, Edwards JK, Hogue SL, Crane MM (2011) Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. BJU Int 108: 1302-1308.
33. Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J (2004) Changing trends of prostate cancer in Asia. Aging Male 7: 120-132.
34. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ (2004) Prostatitis as a risk factor for prostate cancer. Epidemiology 15: 93-99.
35. Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM (2011) Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol 173: 1419-1428.
36. Taiwan Cancer Registry (2010) Cancer Incidence in Taiwan (accessed 29 March 2010). Available at http://tcr.cph.ntu.edu.tw/main.php? Page A5).
37. Taylor ML, Mainous AG III, Wells BJ (2005) Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 37: 506-512.
38. Tseng CH (2011) Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 34: 616-621.
39. van Vuuren SP, Heyns CF, Zarrabi AD (2012) Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate. BJU Int 109: 1194-1197.